GW to file cannabis drug as journal confirms epilepsy success LONDON – GW Pharmaceuticals is defined to file it is cannabis-derived medication with U.S. Regulators imminently, pursuing publication of comprehensive data on its achievement in fighting serious childhood epilepsy. GW initial reported in March 2016 that Epidiolex slice month to month convulsive seizures by 39 % in kids with Dravet symptoms, but full outcomes from the 120-individual research were only published in the brand new Britain Journal of Medication on Wednesday. The journal article also showed that 5 % of individuals stopped having seizures altogether and 43 % saw their seizures cut by half. It includes significantly less than 0.1 % of tetrahydrocannabinol, the substance which makes people high.Sixty-seven % of these older 18 to 34 support legalization of recreational marijuana, weighed against 68 % of 35 – to 44-year-olds and 57 % of these older 55 to 64. That true number dropped to 38 % for all those aged 65 and older. Support for recreational cannabis is apparently driven partly by concerns within the opioid dependency epidemic in america. Somewhat over fifty % of adults, 53 %, said if marijuana were legal, fewer people would die from opioid overdoses.